PL429672A1 - Preparat zawierający ksantohumol i zastosowanie ksantohumolu - Google Patents

Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Info

Publication number
PL429672A1
PL429672A1 PL429672A PL42967219A PL429672A1 PL 429672 A1 PL429672 A1 PL 429672A1 PL 429672 A PL429672 A PL 429672A PL 42967219 A PL42967219 A PL 42967219A PL 429672 A1 PL429672 A1 PL 429672A1
Authority
PL
Poland
Prior art keywords
xanthohumol
preparation containing
chemotherapy
mammal
prevention
Prior art date
Application number
PL429672A
Other languages
English (en)
Inventor
Paweł ZAJDEL
Łukasz PAWEŁEK
Original Assignee
Bioxan Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxan Spółka Z Ograniczoną Odpowiedzialnością filed Critical Bioxan Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL429672A priority Critical patent/PL429672A1/pl
Priority to PCT/IB2020/053577 priority patent/WO2020212882A1/en
Publication of PL429672A1 publication Critical patent/PL429672A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem, zgłoszenia jest preparat zawierający jako substancję czynną ksantohumol lub jego farmaceutycznie dopuszczalną sól lub kompleks ksantohumolu z metalem do stosowania w leczeniu lub zapobieganiu powikłaniom kardiologicznym towarzyszącym chemioterapii u ssaka. Zgłoszenie zawiera też zastosowanie ksantohumolu lub jego farmaceutycznie dopuszczalnej soli lub kompleksu ksantohumolu z metalem w leczeniu lub zapobieganiu powikłaniom kardiologicznym towarzyszącym chemioterapii u ssaka.
PL429672A 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu PL429672A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL429672A PL429672A1 (pl) 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu
PCT/IB2020/053577 WO2020212882A1 (en) 2019-04-17 2020-04-16 A preparation comprising xanthohumol and use of xanthohumol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL429672A PL429672A1 (pl) 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Publications (1)

Publication Number Publication Date
PL429672A1 true PL429672A1 (pl) 2020-10-19

Family

ID=71092563

Family Applications (1)

Application Number Title Priority Date Filing Date
PL429672A PL429672A1 (pl) 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Country Status (2)

Country Link
PL (1) PL429672A1 (pl)
WO (1) WO2020212882A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2714351C (en) * 2008-02-27 2016-01-05 Flaxan Gmbh & Co. Kg Novel compositions containing xanthohumol-cyclodextrin complexes
DE102009015917A1 (de) * 2009-03-13 2010-10-14 Lang, Florian, Prof. Dr. Mittel zur Hemmung und/oder Prophylaxe von Eryptose
US20140045904A1 (en) * 2010-10-10 2014-02-13 Eric Hauser Kuhrts Niacin formulations and methods with reduced flushing side effect
PL2877167T3 (pl) * 2012-07-26 2021-02-08 Arcaini, Antonio Zastosowania kompozycji zawierającej prażony ekstrakt i ksantohumol
EP3020285B1 (de) * 2014-11-11 2019-10-02 Ernst Rainer Weissenbacher Zusammensetzung umfassend sauergut, cerealienmehl und hopfen
AU2017214668B2 (en) * 2016-02-04 2022-12-08 Auransa, Inc. Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US9980925B2 (en) * 2016-04-25 2018-05-29 University Of South Carolina Xanthohumol in antiarrythmic applications
PL235226B1 (pl) * 2016-10-12 2020-06-15 Bioactive Tech Spolka Z Ograniczona Odpowiedzialnoscia Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol
AU2018252153A1 (en) * 2017-04-13 2019-11-07 Jean Paul Remon Xanthohumol-based compositions

Also Published As

Publication number Publication date
WO2020212882A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
CA3148745A1 (en) Kras g12d inhibitors
EP4501932A3 (en) Kras g12c inhibitors
PH12018550062A1 (en) Topical film-forming spray
MX2018010788A (es) Composicion oftalmologica.
CL2020002252A1 (es) Formulación oftálmica.
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
PH12022551241A1 (en) Egfr inhibitors
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
MX2020013352A (es) Tratamiento para migrañas.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX381792B (es) Agente terapéutico para la fibrosis.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX385644B (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
EP3898582A4 (en) NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF
AU2016407426A1 (en) Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist
PL429672A1 (pl) Preparat zawierający ksantohumol i zastosowanie ksantohumolu
HK1252549A1 (zh) 控释tozadenant制剂
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES